1. Home
  2. ANNX vs PKOH Comparison

ANNX vs PKOH Comparison

Compare ANNX & PKOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • PKOH
  • Stock Information
  • Founded
  • ANNX 2011
  • PKOH 1907
  • Country
  • ANNX United States
  • PKOH United States
  • Employees
  • ANNX N/A
  • PKOH N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • PKOH Industrial Specialties
  • Sector
  • ANNX Health Care
  • PKOH Industrials
  • Exchange
  • ANNX Nasdaq
  • PKOH Nasdaq
  • Market Cap
  • ANNX 263.3M
  • PKOH 282.2M
  • IPO Year
  • ANNX 2020
  • PKOH N/A
  • Fundamental
  • Price
  • ANNX $2.56
  • PKOH $18.50
  • Analyst Decision
  • ANNX Strong Buy
  • PKOH
  • Analyst Count
  • ANNX 4
  • PKOH 0
  • Target Price
  • ANNX $12.50
  • PKOH N/A
  • AVG Volume (30 Days)
  • ANNX 1.8M
  • PKOH 30.4K
  • Earning Date
  • ANNX 08-11-2025
  • PKOH 08-06-2025
  • Dividend Yield
  • ANNX N/A
  • PKOH 2.70%
  • EPS Growth
  • ANNX N/A
  • PKOH 144.68
  • EPS
  • ANNX N/A
  • PKOH 2.26
  • Revenue
  • ANNX N/A
  • PKOH $1,644,000,000.00
  • Revenue This Year
  • ANNX N/A
  • PKOH $1.80
  • Revenue Next Year
  • ANNX N/A
  • PKOH $3.97
  • P/E Ratio
  • ANNX N/A
  • PKOH $8.20
  • Revenue Growth
  • ANNX N/A
  • PKOH N/A
  • 52 Week Low
  • ANNX $1.29
  • PKOH $16.81
  • 52 Week High
  • ANNX $7.85
  • PKOH $34.50
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 54.40
  • PKOH 55.53
  • Support Level
  • ANNX $1.85
  • PKOH $18.30
  • Resistance Level
  • ANNX $2.97
  • PKOH $19.74
  • Average True Range (ATR)
  • ANNX 0.27
  • PKOH 0.76
  • MACD
  • ANNX 0.00
  • PKOH 0.17
  • Stochastic Oscillator
  • ANNX 60.32
  • PKOH 62.77

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.

Share on Social Networks: